Ribociclib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ribociclib" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

4doi.org

2^nd place

3europa.eu

68^th place

117^th place

3novartis.com

low place

2tga.gov.au

3,984^th place

2,622^nd place

1hres.ca

low place

1nih.gov

4^th place

1drugs.com

399^th place

333^rd place

1nice.org.uk

3,258^th place

2,666^th place

1fda.gov

447^th place

338^th place

1genengnews.com

low place

6,625^th place

1theguardian.com

12^th place

11^th place

1ascopubs.org

low place

1esmo.org

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

ascopubs.org

hwmaint.meeting.ascopubs.org

Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, et al. (2014). "A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity". Journal of Clinical Oncology. 32 (15 Suppl): 9009. doi:10.1200/jco.2014.32.15_suppl.9009. Archived from the original on 7 October 2015. Retrieved 14 January 2017.

clinicaltrials.gov

Clinical trial number NCT01958021 for "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)" at ClinicalTrials.gov

doi.org

Samson K (2014). "LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers". Oncology Times. 36 (3): 39–40. doi:10.1097/01.COT.0000444043.33304.c1.
Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. (2014). "Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer". Molecular Cancer Therapeutics. 12 (11_Supplement): PR02. doi:10.1158/1535-7163.TARG-13-PR02.
Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, et al. (2014). "A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity". Journal of Clinical Oncology. 32 (15 Suppl): 9009. doi:10.1200/jco.2014.32.15_suppl.9009. Archived from the original on 7 October 2015. Retrieved 14 January 2017.
Wood AC, Krytska K, Ryles H, Sano R, Li N, King F, et al. (2014). "Abstract 1000: Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma". Cancer Research. 74 (19 Supplement): 1000. doi:10.1158/1538-7445.AM2014-1000.

drugs.com

FDA Professional Drug Information on Kisqali. Accessed 8 September 2017.

esmo.org

"ESMO-Magnitude of Clinical Benefit Scale". ESMO. Retrieved 19 October 2021.

europa.eu

ema.europa.eu

"Kisqali EPAR". European Medicines Agency (EMA). 31 March 2023. Retrieved 9 July 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Kisqali: EPAR – Product Information" (PDF). European Medicines Agency. 31 August 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 8 September 2017.
"Kisqali: EPAR – Public assessment report" (PDF). European Medicines Agency. 31 August 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 8 September 2017.

fda.gov

accessdata.fda.gov

"Kisqali (ribociclib) Tablets". U.S. Food and Drug Administration (FDA). 28 March 2017. Retrieved 9 July 2023.

genengnews.com

"FDA Clears Novartis Kisqali for Combination Breast Cancer Therapy". Genetic Engineering and Biotechnology News. 14 March 2017. Retrieved 9 July 2023.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Kisqali". Health Canada. 2 March 2018. Retrieved 8 June 2024.

nice.org.uk

"Thousands of breast cancer patients to have routine access to NICE-approved drug combination". NICE (Press release). Archived from the original on 15 March 2021. Retrieved 8 March 2021.

nih.gov

dailymed.nlm.nih.gov

"Kisqali- ribociclib tablet, film coated". DailyMed. 4 May 2023. Retrieved 9 July 2023.

novartis.com

"Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer" (Press release). Novartis. 1 November 2016. Archived from the original on 25 September 2018. Retrieved 27 January 2017.
"Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer". Novartis (Press release). Retrieved 19 October 2021.

hcp.novartis.com

"Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

theguardian.com

"Life-extending drug for incurable breast cancer approved for NHS use". The Guardian. 26 February 2021. Retrieved 8 March 2021.

web.archive.org

"Thousands of breast cancer patients to have routine access to NICE-approved drug combination". NICE (Press release). Archived from the original on 15 March 2021. Retrieved 8 March 2021.
"Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer" (Press release). Novartis. 1 November 2016. Archived from the original on 25 September 2018. Retrieved 27 January 2017.
"Kisqali: EPAR – Product Information" (PDF). European Medicines Agency. 31 August 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 8 September 2017.
Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, et al. (2014). "A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity". Journal of Clinical Oncology. 32 (15 Suppl): 9009. doi:10.1200/jco.2014.32.15_suppl.9009. Archived from the original on 7 October 2015. Retrieved 14 January 2017.
"Kisqali: EPAR – Public assessment report" (PDF). European Medicines Agency. 31 August 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 8 September 2017.